1. Elisei R, Bottici V, Luchetti F, Di Coscio G, Romei C, Grasso L, et al. Impact of Routine Measurement of Serum Calcitonin on the Diagnosis and Outcome of Medullary Thyroid Cancer: Experience in 10,864 Patients with Nodular Thyroid Disorders. J Clin Endocrinol Metab [Internet]. J Clin Endocrinol Metab; 2004 [cited 2020 Dec 13];89:163–8. Available from: https://pubmed.ncbi.nlm.nih.gov/14715844/
2. Verbeek HHG, de Groot JWB, Sluiter WJ, Muller Kobold AC, van den Heuvel ER, Plukker JTM, et al. Calcitonin testing for detection of medullary thyroid cancer in people with thyroid nodules. Cochrane Database Syst. Rev. John Wiley and Sons Ltd; 2020.
3. Censi S, Cavedon E, Fernando SW, Barollo S, Bertazza L, Zambonin L, et al. Calcitonin measurement and immunoassay interference: A case report and literature review. Clin Chem Lab Med. 2016;54.
4. Alves TG, Kasamatsu TS, Yang JH, Meneghetti MCZ, Mendes A, Kunii IS, et al. Macrocalcitonin is a novel pitfall in the routine of serum calcitonin immunoassay. J Clin Endocrinol Metab [Internet]. Endocrine Society; 2016 [cited 2020 Dec 13];101:653–8. Available from: https://pubmed.ncbi.nlm.nih.gov/26647152/
5. Costante G, Meringolo D, Durante C, Bianchi D, Nocera M, Tumino S, et al. Predictive value of serum calcitonin levels for preoperative diagnosis of medullary thyroid carcinoma in a cohort of 5817 consecutive patients with thyroid nodules. J Clin Endocrinol Metab [Internet]. Endocrine Society; 2007 [cited 2020 Dec 13];92:450–5. Available from: https://pubmed.ncbi.nlm.nih.gov/17119000/
6. Trimboli P, Giovanella L. Serum calcitonin negative medullary thyroid carcinoma: A systematic review of the literature [Internet]. Clin. Chem. Lab. Med. Walter de Gruyter GmbH; 2015 [cited 2020 Dec 13]. p. 1507–14. Available from: https://www.degruyter.com/view/journals/cclm/53/10/article-p1507.xml
7. Bieglmayer C, Vierhapper H, Dudczak R, Niederle B. Measurement of calcitonin by immunoassay analyzers. Clin Chem Lab Med [Internet]. Clin Chem Lab Med; 2007 [cited 2020 Dec 13];45:662–6. Available from: https://pubmed.ncbi.nlm.nih.gov/17484631/
8. Fugazzola L, Di Stefano M, Censi S, Repaci A, Colombo C, Grimaldi F, et al. Basal and stimulated calcitonin for the diagnosis of medullary thyroid cancer: updated thresholds and safety assessment. J Endocrinol Invest [Internet]. Springer; 2020 [cited 2020 Dec 13]; Available from: https://pubmed.ncbi.nlm.nih.gov/32656666/
9. Niederle MB, Scheuba C, Riss P, Selberherr A, Koperek O, Niederle B. Early Diagnosis of Medullary Thyroid Cancer: Are Calcitonin Stimulation Tests Still Indicated in the Era of Highly Sensitive Calcitonin Immunoassays? Thyroid [Internet]. Mary Ann Liebert Inc.; 2020 [cited 2020 Dec 13];30:974–84. Available from: https://pubmed.ncbi.nlm.nih.gov/32056502/
10. Alicia Algeciras-Schimnich, Carol MP, J. Paul Theobald, Mary SF, Stefan KG. Procalcitonin: A marker for the diagnosis and follow-up of patients with medullary thyroid carcinoma. J Clin Endocrinol Metab [Internet]. Endocrine Society; 2009 [cited 2020 Dec 21];94:861–8. Available from: /pmc/articles/PMC2730230/?report=abstract
11. Trimboli P, Seregni E, Treglia G, Alevizaki M, Giovanella L. Procalcitonin for detecting medullary thyroid carcinoma: A systematic review [Internet]. Endocr. Relat. Cancer. BioScientifica Ltd.; 2015 [cited 2020 Dec 21]. p. R157–64. Available from: https://pubmed.ncbi.nlm.nih.gov/25934688/
12. Walter MA, Meier C, Radimerski T, Iten F, Kränzlin M, Müller-Brand J, et al. Procalcitonin levels predict clinical course and progression-free survival in patients with medullary thyroid cancer. Cancer [Internet]. Cancer; 2010 [cited 2020 Dec 21];116:31–40. Available from: https://pubmed.ncbi.nlm.nih.gov/19890958/
13. Bolko P, Manuszewska-Jopek E, Michałek K, Waśko R, Jaskuła M, Sowiński J. Efficacy of Procalcitonin Measurement in Patients after Total Thyroidectomy Due to Medullary Thyroid Carcinoma. Arch Immunol Ther Exp (Warsz). 2003;51:415–9.
14. Kratzsch J, Petzold A, Raue F, Reinhardt W, Bröcker-Preuß M, Görges R, et al. Basal and stimulated calcitonin and procalcitonin by various assays in patients with and without medullary thyroid cancer. Clin Chem [Internet]. Clin Chem; 2011 [cited 2020 Dec 21];57:467–74. Available from: https://pubmed.ncbi.nlm.nih.gov/21159900/
15. Kaczka K, Mikosiński S, Fendler W, Celnik A, Pomorski L. Calcitonin and Procalcitonin in Patients with Medullary Thyroid Cancer or Bacterial Infection* Kalcytonina i prokalcytonina u pacjentów z rakiem rdzeniastym tarczycy lub infekcją bakteryjną.
16. Trimboli P, Lauretta R, Barnabei A, Valabrega S, Romanelli F, Giovanella L, et al. Procalcitonin as a postoperative marker in the follow-up of patients affected by medullary thyroid carcinoma. Int J Biol Markers [Internet]. SAGE Publications Ltd; 2018 [cited 2020 Dec 21];33:156–60. Available from: https://pubmed.ncbi.nlm.nih.gov/29707993/
17. Machens A, Lorenz K, Dralle H. Utility of serum procalcitonin for screening and risk stratification of medullary thyroid cancer. J Clin Endocrinol Metab [Internet]. Endocrine Society; 2014 [cited 2020 Dec 21];99:2986–94. Available from: https://pubmed.ncbi.nlm.nih.gov/24840813/
18. Giovanella L, Imperiali M, Piccardo A, Taborelli M, Verburg FA, Daurizio F, et al. Procalcitonin measurement to screen medullary thyroid carcinoma: A prospective evaluation in a series of 2705 patients with thyroid nodules. Eur J Clin Invest [Internet]. Blackwell Publishing Ltd; 2018 [cited 2020 Dec 21];48. Available from: https://pubmed.ncbi.nlm.nih.gov/29635700/
19. Giovanella L, Verburg FA, Imperiali M, Valabrega S, Trimboli P, Ceriani L. Comparison of serum calcitonin and procalcitonin in detecting medullary thyroid carcinoma among patients with thyroid nodules. Clin Chem Lab Med [Internet]. Clin Chem Lab Med; 2013 [cited 2020 Dec 21];51:1477–81. Available from: https://pubmed.ncbi.nlm.nih.gov/23314540/
20. Mian C, Perrino M, Colombo C, Cavedon E, Pennelli G, Ferrero S, et al. Refining Calcium Test for the Diagnosis of Medullary Thyroid Cancer: Cutoffs, Procedures, and Safety. J Clin Endocrinol Metab [Internet]. 2014 [cited 2018 Jul 10];99:1656–64. Available from: http://www.ncbi.nlm.nih.gov/pubmed/24552221
21. Wells SA, Asa SL, Dralle H, Elisei R, Evans DB, Gagel RF, et al. Revised American Thyroid Association Guidelines for the Management of Medullary Thyroid Carcinoma. Thyroid [Internet]. 2015 [cited 2019 Aug 16];25:567–610. Available from: http://www.ncbi.nlm.nih.gov/pubmed/25810047
22. Haugen BR, Alexander EK, Bible KC, Doherty GM, Mandel SJ, Nikiforov YE, et al. 2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer. Thyroid [Internet]. 2016 [cited 2018 Jun 9];26:1–133. Available from: http://online.liebertpub.com/doi/10.1089/thy.2015.0020
23. Vardarli I, Weber M, Weidemann F, Führer D, Herrmann K, Görges R. Diagnostic accuracy of routine calcitonin measurement for the detection of medullary thyroid carcinoma in the management of patients with nodular thyroid disease: A meta-analysis. Endocr Connect [Internet]. BioScientifica Ltd.; 2021 [cited 2021 Jun 3];10:358–70. Available from: https://pubmed.ncbi.nlm.nih.gov/33638941/
24. Fortunato A. A new sensitive automated assay for procalcitonin detection: LIAISON® BRAHMS PCT® II GEN. Pract Lab Med [Internet]. Elsevier B.V.; 2016 [cited 2021 Jan 7];6:1–7. Available from: https://pubmed.ncbi.nlm.nih.gov/28856207/
25. B·R·A·H·M·S PCT direct - B·R·A·H·M·S PCT (Procalcitonin) [Internet]. [cited 2021 Jan 7]. Available from: https://www.procalcitonin.com/pct-assays/pct-direct.html#assay-characteristics